Moderna, Inc. plans to file for US Food and Drug Administration authorization of its bivalent, Omicron-specific COVID-19 vaccine candidate in the coming weeks and is hoping by late summer to be ready to start shipments in time for the fall.
The company announced positive data on 8 June from the Phase II/III study of mRNA-1273.214, showing superiority against the Omicron variant compared with the FDA-approved Spikevax vaccine, originally known as...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?